Superintendent Office, Antai Medical Care Cooperation, Antai Tian-Sheng Memorial Hospital , Pingtung, Taiwan.
J Agric Food Chem. 2014 Feb 19;62(7):1572-80. doi: 10.1021/jf405235j. Epub 2014 Feb 6.
A previous study reported that anthocyanins from roselle (Hibiscus sabdariffa L.) showed significant anticancer activity in human promyelocytic leukemia cells. To explore the antitumor effect of anthocyanin, a roselle bioactive polyphenol in a rat model of chemical-induced leukemia was assayed. Anthocyanin extract of roselle (Hibiscus anthocyanins, HAs) was supplemented in the diet (0.1 and 0.2%). This study was carried out to evaluate the protective effect of HAs on N-nitrosomethylurea (NMU)-induced leukemia of rats. The study employed male Sprague-Dawley rats (n = 48), and leukemia was induced by intravenous injection of 35 mg kg(-1) body weight of NMU dissolved in physiologic saline solution. The rats were divided into four groups (n = 12): control, NMU only, and HAs groups that received different doses of HAs (0.1 and 0.2%) daily, orally, after NMU injection. After 220 days, the animals were killed, and the following parameters were assessed: morphological observation, hematology examination, histopathological assessment, and biochemical assay. When compared with the NMU-only group, HAs significantly prevented loss of organ weight and ameliorated the impairment of morphology, hematology, and histopathology. Treatment with HAs caused reduction in the levels of AST, ALT, uric acid, and MPO. Also, the results showed that oral administration of HAs (0.2%) remarkably inhibited progression of NMU-induced leukemia by approximately 33.3% in rats. This is the first report to demonstrate that the sequential administration of HAs followed by NMU resulted in an antileukemic activity in vivo.
先前的研究表明,洛神花(Hibiscus sabdariffa L.)中的花色苷具有显著的抗人类早幼粒细胞白血病细胞的抗癌活性。为了探究花色苷的抗肿瘤作用,在化学诱导的白血病大鼠模型中检测了洛神花的一种生物活性多酚类化合物花色苷。在饮食中补充洛神花花色苷提取物(Hibiscus anthocyanins,HAs)(0.1%和 0.2%)。本研究旨在评估 HAs 对 N-亚硝基甲基脲(N-nitrosomethylurea,NMU)诱导的大鼠白血病的保护作用。本研究采用雄性 Sprague-Dawley 大鼠(n = 48),通过静脉注射 35 mg kg-1体重溶于生理盐水的 NMU 诱导白血病。将大鼠分为四组(n = 12):对照组、NMU 组、HAs 组,在 NMU 注射后每天口服不同剂量的 HAs(0.1%和 0.2%)。220 天后,处死动物,评估以下参数:形态学观察、血液学检查、组织病理学评估和生化测定。与 NMU 组相比,HAs 显著防止了器官重量的损失,并改善了形态、血液学和组织病理学的损伤。HAs 治疗降低了 AST、ALT、尿酸和 MPO 的水平。此外,结果表明,口服 HAs(0.2%)可显著抑制 NMU 诱导的白血病在大鼠体内的进展,约 33.3%。这是首次报道表明 HAs 的序贯给药在体内具有抗白血病活性。